Dear ,

In the current issue of the OncoWuXi Newsletter, we would like to share with you the newly developed capabilities of our FACS platform. Other interesting topics covered in this issue include the ER positive or HER2 positive breast cancer PDX models, and EGFR exon20 insertion PDX models.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of WuXi Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
Immuno-Oncology
WuXi AppTec OIU FACS Platform
(1)  Overview of the FACS facility and services for preclinical discovery

(2)  Phenotypic analysis of tumor infiltrating leukocytes (TILs)
  • Workflow of TILs analysis for in vivo drug efficacy study
  • Murine TILs composition and its corresponding biomarker analysis
  • Basic panel options for flexible design
  • Baselines of TILs subpopulations in different syngeneic models
  • Case studies of leukocyte analysis for different cell populations in tumors or immune organs using different syngeneic models
  • Comprehensive immune-profiling by flow cytometry in a single panel

(3)  Intracellular cytokine staining and analysis by FACS

(4)  Analysis on major cell populations (24 markers) in peripheral blood by a single panel

(5)  Secreted cytokine analysis by CBA and ELISA

(6)  In vivo phosphoflow cytometry analysis: pSTAT5 detection in mouse PBMCs after in vivo mIL-2 stimulation

(7)  Multiple dimensional analysis of flow cytometry data

(8)  Case study of TILs analysis in humanized mouse model after checkpoint inhibitor treatment

(9)  Case study of driver gene verification by FACS

(10) Introduction of clinically relevant CAP-certified FACS lab

(11) Workflow of clinical project by FACS

(12) Clinically relevant assays (CAP-certified) and case studies
  • TBNK (T, B, NK cells) cell numeration in human peripheral blood
  • PK/PD assay for CAR-T clinical study
  • Receptor occupancy assay
  • Immune-profiling and biomarker detection in lung cancer PDX model tumor tissue


Targeted Oncology
ER Positive Breast Cancer PDX Models
(1)  Overview of breast cancer and ER

(2)  ER positive breast cancer PDX models
  • BR-05-0380 and BR-05-0436E PDX models, characterized by ER, PR, HER2 IHC staining, and validated with Tamoxifen, Palbociclib, Herceptin or Fulvestrant


HER2 Positive Breast Cancer PDX Models

(1)  Overview of breast cancer and HER2

(2)  HER2 positive breast cancer PDX models

Translational Oncology
EGFR Exon20 Insertion PDX Models
1)  EGFR background as a drug target
  • EGFR biology and the role of EGFR mutations in cancer
  • EGFR inhibitors

(2)  PDX models with EGFR Exon20 insertion
  • LU-01-0426 and LU-01-0493 lung cancer PDX models, validated with Afatinib, Osimertinib or Poziotinib


We sincerely appreciate your interest, time and support, and would like to hear your feedback so we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

 
Best regards,
WuXi AppTec OncoWuXi Team